MX354535B - TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß. - Google Patents
TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß.Info
- Publication number
- MX354535B MX354535B MX2013002390A MX2013002390A MX354535B MX 354535 B MX354535 B MX 354535B MX 2013002390 A MX2013002390 A MX 2013002390A MX 2013002390 A MX2013002390 A MX 2013002390A MX 354535 B MX354535 B MX 354535B
- Authority
- MX
- Mexico
- Prior art keywords
- myocardial infarction
- tgf
- treatment
- beta antagonists
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37931510P | 2010-09-01 | 2010-09-01 | |
| PCT/US2011/001536 WO2012030394A1 (en) | 2010-09-01 | 2011-09-01 | Treatment of myocardial infarction using tgf - beta antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013002390A MX2013002390A (es) | 2013-08-27 |
| MX354535B true MX354535B (es) | 2018-03-09 |
Family
ID=44654454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013002390A MX354535B (es) | 2010-09-01 | 2011-09-01 | TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20130330352A1 (enExample) |
| EP (1) | EP2611831B1 (enExample) |
| JP (2) | JP6377348B2 (enExample) |
| KR (1) | KR101939965B1 (enExample) |
| CN (1) | CN103201292B (enExample) |
| BR (1) | BR112013004850B1 (enExample) |
| CA (1) | CA2809568C (enExample) |
| CL (1) | CL2013000586A1 (enExample) |
| ES (1) | ES2715177T3 (enExample) |
| IL (1) | IL225018A (enExample) |
| MX (1) | MX354535B (enExample) |
| MY (1) | MY165160A (enExample) |
| NZ (2) | NZ608813A (enExample) |
| PH (1) | PH12013500411A1 (enExample) |
| PL (1) | PL2611831T3 (enExample) |
| RU (1) | RU2637088C2 (enExample) |
| SG (2) | SG187953A1 (enExample) |
| TR (1) | TR201903101T4 (enExample) |
| WO (1) | WO2012030394A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010216095B2 (en) * | 2009-02-18 | 2015-10-08 | Cormatrix Cardiovascular, Inc. | Compositions and methods for preventing cardiac arrhythmia |
| TWI664979B (zh) * | 2013-03-11 | 2019-07-11 | 健臻公司 | 經生物工程之抗-ＴＧＦ-β抗體及抗原結合片段 |
| HK1225740A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma Inc. | TGF-β受体II型变体及其用途 |
| WO2016100233A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| US11253546B2 (en) | 2014-12-15 | 2022-02-22 | The Regents Of The University Of California | Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20 |
| CN116327952A (zh) | 2015-08-04 | 2023-06-27 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
| EP3368571B1 (en) | 2015-10-30 | 2022-12-07 | The Regents of The University of California | Transforming growth factor-beta-responsive polypeptides and their methods for use |
| US9989543B2 (en) | 2016-01-11 | 2018-06-05 | Autotelic, Llc | Composition, device, and method for detecting olmesartan and improving compliance in treating hypertension |
| US20170218040A1 (en) * | 2016-02-02 | 2017-08-03 | Julio A. Camarero Palao | Proteolically resistant cyclotides with angiotensin 1-7 like activity |
| JP2019533003A (ja) * | 2016-08-11 | 2019-11-14 | プレシセラ，インコーポレイテッド | ＴＧＦ−βアンタゴニストコンジュゲート |
| EP3628049B1 (en) | 2017-05-04 | 2023-05-10 | Acceleron Pharma Inc. | Tgf-beta receptor type ii fusion proteins and uses thereof |
| TW202334179A (zh) | 2021-09-30 | 2023-09-01 | 日商肽夢想股份有限公司 | 胜肽 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| ATE439592T1 (de) | 1998-12-10 | 2009-08-15 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
| US7763580B2 (en) * | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| KR101245983B1 (ko) | 2004-03-31 | 2013-06-28 | 제넨테크, 인크. | 인간화 항-ｔｇｆ-베타 항체 |
| US20070014733A1 (en) * | 2005-01-31 | 2007-01-18 | O'donnell John P | Hydroxylated nebivolol metabolites |
| MX2007009545A (es) * | 2005-02-08 | 2008-03-11 | Genzyme Corp | Anticuerpos para tgfbeta. |
| JP2012515800A (ja) * | 2009-01-26 | 2012-07-12 | インターミューン， インコーポレイテッド | 急性心筋梗塞および関連障害を処置するための方法 |
| ITMI20110376A1 (it) | 2011-03-10 | 2012-09-11 | Wilic Sarl | Aerogeneratore raffreddato a fluido |
-
2011
- 2011-09-01 MY MYPI2013000675A patent/MY165160A/en unknown
- 2011-09-01 JP JP2013527063A patent/JP6377348B2/ja not_active Expired - Fee Related
- 2011-09-01 SG SG2013013875A patent/SG187953A1/en unknown
- 2011-09-01 NZ NZ608813A patent/NZ608813A/en not_active IP Right Cessation
- 2011-09-01 RU RU2013114365A patent/RU2637088C2/ru active
- 2011-09-01 NZ NZ624382A patent/NZ624382A/en not_active IP Right Cessation
- 2011-09-01 WO PCT/US2011/001536 patent/WO2012030394A1/en not_active Ceased
- 2011-09-01 ES ES11758276T patent/ES2715177T3/es active Active
- 2011-09-01 PL PL11758276T patent/PL2611831T3/pl unknown
- 2011-09-01 EP EP11758276.7A patent/EP2611831B1/en active Active
- 2011-09-01 TR TR2019/03101T patent/TR201903101T4/tr unknown
- 2011-09-01 PH PH1/2013/500411A patent/PH12013500411A1/en unknown
- 2011-09-01 BR BR112013004850A patent/BR112013004850B1/pt not_active IP Right Cessation
- 2011-09-01 US US13/819,393 patent/US20130330352A1/en not_active Abandoned
- 2011-09-01 CN CN201180052346.0A patent/CN103201292B/zh not_active Expired - Fee Related
- 2011-09-01 CA CA2809568A patent/CA2809568C/en not_active Expired - Fee Related
- 2011-09-01 MX MX2013002390A patent/MX354535B/es active IP Right Grant
- 2011-09-01 SG SG10201506909PA patent/SG10201506909PA/en unknown
- 2011-09-01 KR KR1020137008326A patent/KR101939965B1/ko not_active Expired - Fee Related
-
2013
- 2013-02-28 CL CL2013000586A patent/CL2013000586A1/es unknown
- 2013-02-28 IL IL225018A patent/IL225018A/en active IP Right Grant
-
2016
- 2016-12-12 US US15/376,358 patent/US10633437B2/en not_active Expired - Fee Related
-
2017
- 2017-04-20 JP JP2017083499A patent/JP2017193543A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX354535B (es) | TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß. | |
| EA201171367A1 (ru) | Винилиндазолильные соединения | |
| CY1121419T1 (el) | Αναστολη της φουκοσυλιωσης των πρωτεϊνων in vivo χρησιμοποιωντας αναλογα φουκοζης | |
| EA201390772A1 (ru) | Новые соли и полиморфные формы афатиниба | |
| EA201270619A1 (ru) | Применение бетанехола для лечения ксеростомии | |
| PA8852901A1 (es) | Inhibidores de proteina cinasa | |
| CY1117678T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
| EA201390609A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
| EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
| TR201813877T4 (tr) | Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler. | |
| MX355543B (es) | Macrociclos peptidomiméticos. | |
| EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
| EA201300583A1 (ru) | Вазопротективное и кардиопротективное противодиабетическое лечение | |
| EA201170227A1 (ru) | Имидазолкарбоксамиды | |
| ECSP11010831A (es) | Compuestos orgánicos para la cicatrización de heridas | |
| UY34305A (es) | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar | |
| MX2021014242A (es) | Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora. | |
| MX2021001169A (es) | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas. | |
| EA201170252A1 (ru) | Амидофеноксиндазолы в качестве ингибиторов c-мет | |
| HRP20181727T1 (hr) | Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška | |
| EA201390428A1 (ru) | Композиции и способы лечения легочной гипертензии | |
| EA201600495A1 (ru) | Пролекарство адреномедуллина на основе полиэтиленгликоля и его применение | |
| CO6362012A2 (es) | Clohidarto de nalmefeno dihidratado | |
| EA201390799A1 (ru) | Триазолопиридины | |
| WO2012158672A3 (en) | Compounds for use in treatment of mucositis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |